Targeting Mitochondrial Dysfunction
Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.
View Candidate
Innovative Pipeline of First-In-Class Products
Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.
View Pipeline
Backed by Strong Leadership
Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.
Meet Our Team
Latest News
Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 1) in Japan for the Treatment of Type 2 Diabetes
Imeglimin Phase 3 trial (TIMES 1) met its primary and main secondary endpoints Imeglimin Phase 3 TIMES 3 16-week, double-blind, placebo controlled, randomized part…
Read this Press Release: Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 1) in Japan for the Treatment of Type 2 DiabetesPoxel Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose Trial
PXL065 observed to have a favorable safety, tolerability and pharmacokinetic profile in the Phase 1a trial PXL065 is advancing into a Phase 1b multiple ascending dose…
Read this Press Release: Poxel Announces Favorable Results for PXL065 Phase 1a Single Ascending Dose TrialPoxel Announces First Quarter 2019 Financial Update
LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders,…
Read this Press Release: Poxel Announces First Quarter 2019 Financial Update
